Valos

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valos

What is Valos? (Cefadroxil)

Property Description
Active Ingredient Cefadroxil (Monohydrate)
Form Capsule, Tablet, Oral Suspension
Pharmacological Class First Generation Cephalosporin, Antibiotic
General Purpose Treatment of systemic bacterial infections
Origin Semisynthetic

What Pharmacological Class Does Valos Belong To?

Valos is the trade name for a prescription medication whose active substance, Cefadroxil, classifies it as a First Generation Cephalosporin antibiotic. This classification is based on Cefadroxil being a semisynthetic compound, meaning its chemical structure is deliberately modified from a natural precursor to enhance its stability and therapeutic profile. First Generation Cephalosporins are clinically recognized for their foundational utility against many common bacterial pathogens, establishing the drug’s role as a broad-scope, systemic anti-infective agent.

What is Cefadroxil and How is Valos Formulated?

The core component of Valos is the single active ingredient, Cefadroxil. A key differentiating feature is Cefadroxil’s molecular stability, which permits its administration orally for reliable absorption and systemic effect, unlike some older antibiotic classes that require injection. Valos is supplied in multiple dose forms, including compressed solid tablets and capsules, and as a powder for reconstitution into an oral suspension. The availability of a liquid suspension is particularly beneficial, often targeting patient groups such as children or individuals who experience difficulty swallowing solid medication.

What is the General Purpose of this Antibiotic?

The primary purpose of Valos is to serve as a bactericidal agent, actively killing the bacteria responsible for an illness. The drug achieves its therapeutic goal by specifically targeting and inhibiting the synthesis of the rigid bacterial cell wall, a structure essential for the organism's survival. This action causes the bacterial cells to destabilize and rupture, which is fundamental to its role in successfully clearing common bacterial illnesses.

What side effects are possible with Valos?

Possible Side Effects and Safety Information

The official safety profile of Valos (Cefadroxil) is structured by regulatory authorities to define and categorize documented adverse reactions and necessary safety precautions. Adverse reactions are grouped by the physiological system affected and classified by their observed frequency, establishing the drug's risk profile.


Adverse Reaction Scope

Category Description
Frequency classification Reactions are classified as Common (e.g., Diarrhea, Nausea, Rash), Uncommon (e.g., Pruritus), or Rare (e.g., Thrombocytopenia, Interstitial nephritis), as documented in regulatory labeling. The frequency of some severe events is classified as Not Known (e.g., Pseudomembranous colitis).
System-organ classes involved Documented effects primarily involve Gastrointestinal disorders (e.g., abdominal pain, dyspepsia), Skin and subcutaneous tissue disorders (e.g., urticaria, allergic exanthema), Immune system disorders, and Infections and infestations (e.g., vaginal candidiasis).
Serious adverse reactions The label explicitly notes rare, clinically significant reactions, including anaphylactic shock (a severe allergic reaction) and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS). Pseudomembranous colitis is also identified as a serious gastrointestinal event that may occur during or after treatment.

Safety Restrictions and Considerations

Official labeling contraindicates the use of Cefadroxil in patients with a known hypersensitivity or allergy to cephalosporins. Caution is mandated for patients with a history of severe penicillin allergy due to the potential for cross-reactivity.

Specific safety considerations exist for special populations: the elimination of the drug is slower in individuals with renal impairment, necessitating caution. Furthermore, the label advises caution in patients with a history of gastrointestinal disease, particularly colitis. Some rare effects, such as blood disorders, have been noted during prolonged use.

Overdose and Emergency Response

The official regulatory documentation for Valos (Cefadroxil) overdose emphasizes the need for immediate emergency intervention based on the resulting clinical manifestations. The primary documented risk is the potential for central nervous system effects, which may include seizures.

Overdose Status Required Action (Regulatory Mandate)
Severe or Life-Threatening Call emergency services (911) immediately if symptoms include a seizure, collapse, trouble breathing, or inability to be awakened.
General Overdose Suspicion Call the poison control helpline for advice and guidance.

Overdose Classifications (High-Level)

Severity classification of an overdose is determined by the presentation of symptoms, ranging from general suspicion requiring Poison Control contact to severe outcomes that mandate immediate emergency services. The drug's substantial excretion by the kidney is noted as a factor in its general safety profile, but no specific population-based management difference for overdose is explicitly documented.

Official overdose statements affirm that no specific antidote is known for Cefadroxil. Consequently, the established management strategy is defined as being symptomatic and supportive, focusing on maintaining vital functions and treating any observable clinical signs of toxicity.

This profile confirms that emergency help-seeking criteria are strictly governed by the patient's clinical presentation, exactly as detailed in official prescribing information.

Therapeutic Uses of Valos

What Valos Treats: Main Uses and Benefits

Valos (Cefadroxil) is commonly used for the targeted management of infections caused by susceptible bacterial pathogens, with the intention of supporting the management of the overall symptom burden associated with the illness. The medication is applied across several domains when symptoms create noticeable interference with daily stability.

The medication is commonly used across conditions presenting with acute episodes of localized bacterial growth, including infections of the skin and soft tissues (like cellulitis and impetigo), uncomplicated urinary tract infections (UTIs), and specific upper respiratory tract infections such as pharyngitis (strep throat) and tonsillitis.

“This medication offers symptomatic relief that helps patients cope more steadily with difficult acute episodes, providing supportive assistance during phases of increased distress or discomfort.”

Acute Infections of the Skin and Soft Tissues

This antibiotic is commonly used across conditions presenting with acute episodes of localized bacterial growth. It is applied in addressing symptom patterns such as pronounced redness, swelling, tenderness, and localized pain associated with skin infections. Valos is applied in addressing the infection, which assists with maintaining functional stability and easing the overall symptom load.


Quick Fact: Supports Management of Urinary Discomfort

Valos is relevant when supportive symptom management is appropriate for acute UTIs, addressing symptoms like painful or burning urination (dysuria) and urinary frequency.


Treatment for Genitourinary and Upper Respiratory Symptom Clusters

Valos is applied in clinical settings that involve acute or unstable symptom patterns in the urinary and upper respiratory tracts. By addressing these infections, the medication offers symptomatic relief that helps patients cope more steadily with difficult acute episodes. It is also relevant when supportive symptom management is appropriate in specific preventative clinical contexts for at-risk patients who are undergoing certain invasive procedures.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Valos?

The regulatory profile for Valos (Cefadroxil) establishes specific, official rules defining who is eligible to use the medicine based on absolute contraindications and conditional restrictions.

Populations for Whom Use is Prohibited or Restricted

Classification Official Regulatory Rule
Absolute Contraindication Patients with a known allergy to the cephalosporin class of antibiotics, or a history of severe hypersensitivity reactions to penicillins due to cross-sensitivity risk.
Restricted/Conditional Use Use requires special caution in patients with markedly impaired renal function (kidney disease), as the drug is substantially excreted by the kidney.
Comorbidity Restriction Use should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

Age and Physiological Status

Population Group Regulatory Eligibility Status
Established Use Adults and Pediatric Patients are approved for use according to labeled indications.
Older Adults Use is established, but caution is advised, as this group is more likely to require renal function monitoring.
Pregnancy/Lactation Conditional Use (FDA Category B). Use during pregnancy is advised only if clearly needed. Use during lactation is permitted with caution.

The eligibility structure emphasizes absolute prohibition based on allergy history and mandates careful consideration for use in the presence of organ impairment or specific comorbid conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Valos (Cefadroxil) details specific interaction patterns with other medicines, products, and diagnostic procedures. This information strictly describes documented label-based constraints.

Drug and Substance Interactions

Interacting Substance Official Interaction Pattern Regulatory Status
Bacteriostatic Antibiotics Potential antagonistic effect is documented; co-administration may reduce Valos's bactericidal efficacy. Contraindicated Combination
Probenecid Reduces the renal elimination of Valos by inhibiting tubular secretion, resulting in increased plasma concentrations. Pharmacokinetic Interaction
Nephrotoxic Agents Increased risk of potentiated nephrotoxic effects due to an additive toxicity profile. Caution Required
Anticoagulants (e.g., Warfarin) Potential to alter coagulation parameters; requires monitoring during co-administration to manage bleeding risk. Pharmacodynamic Risk

Other Interaction Constraints

Valos is confirmed to be administered without regard to meals, as food does not alter the extent of drug absorption, meaning no mandatory timing separation rules exist. The drug can also cause procedural constraints, specifically a transient positive direct Coombs test result and false-positive reactions when testing for urine glucose using certain non-enzyme based methods.

The interaction structure is particularly sensitive to impaired renal function, as reduced clearance can lead to drug accumulation, which may increase the clinical significance of documented interactions.

Mechanism of Action

Valos (Cefadroxil) acts via a bactericidal mechanism defined by its targeted interference with bacterial cell wall biosynthesis. The primary action involves the drug’s high-affinity binding to bacterial Penicillin-Binding Proteins (PBPs), a class of transpeptidase enzymes crucial for cell wall construction. Valos acts as a beta-lactam, which achieves irreversible covalent inhibition by acylating the serine residue within the PBP active site, permanently deactivating the enzyme. This targeted molecular interference represents the initial event in the mechanistic sequence.

By deactivating the PBPs, Valos effectively halts the crucial peptidoglycan cross-linking pathway, the final stage of cell wall biosynthesis. This structural failure prevents the formation of a rigid protective barrier, causing the cell to lose its structural integrity. The subsequent loss of osmotic balance results in osmotic lysis, leading to the breakdown of the bacterial cell population. The mechanism is constrained by bacterial production of beta-lactamase enzymes, which inactivate the drug before it reaches its target, and the presence of mutated PBPs with reduced binding affinity.

Dosage and Administration Information

Instruction Map: How to use Valos — Official Administration Guidelines

This information is based on the established structural requirements for the Dosage and Administration of the medication.

Instruction Component Official Guideline
Route of administration: Intratumoral Injection (IT) and/or Intravenous Infusion (IV).
Dosing schedule: 5 imes 10^11 viral particles (VP) per dose. Administer once every 21 days.
Preparation requirements (if applicable): 1. Aseptically reconstitute the lyophilized powder with the specified volume of Sterile Water for Injection, USP. 2. Dilute the reconstituted product into 0.9% Sodium Chloride Injection to the final volume.
Age-group administration rules: Safety and effectiveness have not been established in pediatric patients. No dose adjustment is recommended for mild to moderate renal/hepatic impairment.
Missed-dose rules: If a dose is missed, administer the dose as soon as possible and resume the next scheduled dose 21 days after the missed dose administration.
Special procedural conditions: The infusion must be administered slowly and continuously over a period of 60 minutes. The prepared solution must not be filtered.

Resulting Procedural Structure

The official procedural sequence for administering Valos is:

  • The lyophilized form must first be reconstituted with the specified volume of diluent.
  • The resulting solution must then be diluted immediately into 0.9% Sodium Chloride Injection to the final administration volume.
  • The full dose is administered via intravenous infusion, observing the mandatory 60-minute duration to manage the delivery rate.
  • The dosing frequency follows a cyclic pattern, requiring administration every 21 days.

Connection to the overall use protocol: The administration guidelines mandate the precise method of reconstitution and dilution for Valos, ensuring proper stability and concentration before use. This structure establishes a strict cyclic dosing regimen and imposes constraints, such as the minimum 60-minute infusion time, which defines the standardized use of the medicine.

Recent Clinical Evidence

Valos: Recent Clinical Evidence

Evidence Base for Skin and Soft Tissue Infections

Valos has been studied for conditions associated with acute or disruptive episodes of bacterial growth in the skin and underlying soft tissues, such as cellulitis and impetigo. The research structure includes Comparative Clinical Trials, where Valos was evaluated in patient populations against other common treatments, and traditional Clinical Trials. The primary outcomes research examined were the clinical outcome measurements and the microbiological outcome of susceptible pathogens like staphylococci and streptococci. Findings describe patterns observed in the studies over short, defined time intervals, typically lasting 7 to 10 days.

Evidence Base for Uncomplicated Urinary Tract Infections (UTIs)

Research on Valos was studied for conditions characterized by fluctuating or episodic manifestations in the urinary tract, specifically uncomplicated UTIs. Research examined two primary areas related to the use of Valos: the microbiological outcome of specific bacteria, such as E. coli, from the urinary tract, and the evaluation of outcomes related to physical discomfort. Studies reported how symptoms evolved in the observed populations over the short-term treatment duration.


What Remains Unclear or Under Study?

Evidence highlights what is known about Valos based on the existing body of research, but also clarifies areas where certainty remains low or research is structurally limited. Long-term effects are not fully established because the evidence base contains limited information for long-term outcomes or how often infections or symptoms recurred months or years after treatment was completed. This means the durability of the initial response is an area where certainty remains low.

Data for certain groups remain insufficient. For instance, evidence is limited concerning response patterns in a sufficient number of older patients (over 65) with upper respiratory infections. Additionally, the results apply only to the populations studied, meaning the applicability to individuals with complex, chronic underlying conditions remains uncertain.

Key Studies & References

  1. Cefadroxil Monograph (MedlinePlus Drug Information)
  2. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections

Frequently Asked Questions (FAQ)

Common questions about Valos (FAQ)

Q: Are there any food or drink restrictions while taking Valos?

Official product information indicates that the drug can be taken without regard to food, meaning meals do not interfere with its absorption. Regarding beverages, regulatory documents do not typically list specific restrictions for common drinks, but regulatory warnings for antibiotics commonly advise caution with alcohol consumption during the treatment period.

Q: Will I feel different right after starting Valos?

Following administration, official reports show that some common adverse reactions, such as nausea or diarrhea, may begin. Additionally, rare side effects, including dizziness or headache, have been reported in clinical experience. These are part of the known safety profile described in official documents.

Q: What does the research say about using Valos in children?

The use of Valos is established for pediatric patients for specific conditions, according to official labeling. For children, the medicine is commonly provided in an oral suspension (liquid) form. The necessary adjustments to the amount given are calculated based on the child's body weight and the specific condition being addressed.

Q: What is the difference between Valos and the generic version?

Valos is the commercial brand name for the active ingredient, which is known generically as Cefadroxil. Regulatory standards require that the generic version contain the exact same active medicine and meet identical quality requirements, meaning they are considered equivalent in terms of therapeutic substance.

Q: How does the time of day affect Valos use?

Official guidelines state that Valos administration does not need to be timed around meals. Consistency in administration time on the scheduled day is advised to help maintain steady concentrations of the medicine in the body.

Q: What does the 'contraindications' section mean for Valos?

The 'contraindications' section in regulatory labeling defines conditions or circumstances where the drug must not be used because the risk of harm is too high. For Valos, a primary contraindication is a known history of allergy to the cephalosporin class of antibiotics.

Q: Is it generally expected that Valos will cure the condition?

Valos is classified as a bactericidal agent, meaning its purpose is to actively kill the specific bacteria responsible for the infection. The therapeutic goal, as defined in clinical studies, is the elimination of these susceptible pathogens, which often leads to the resolution of symptoms.

Q: Can Valos cause changes in mood?

Official summaries of adverse reactions have sometimes included rare reports of effects on the nervous system, such as feeling nervousness or experiencing sleeplessness. Other effects like headaches and dizziness have also been reported in clinical experience.

Q: Does Valos interact with over-the-counter pain relievers?

Official product labeling details specific interactions with certain classes of medicines, such as anticoagulants or nephrotoxic agents. However, common over-the-counter pain relievers are not typically listed in the main drug interaction tables found in regulatory documents.

Q: Is Valos described as a controlled substance?

Official regulatory scheduling information indicates that Valos is not designated as a controlled substance under government acts like the U.S. Controlled Substances Act. It is classified simply as a prescription antibiotic.

Q: Can Valos affect driving or operating machinery?

Adverse reactions, including reports of dizziness, headache, and general fatigue, have been noted in the safety profile. The occurrence of such effects may influence a patient's ability to drive or operate complex machinery.

Q: Is it true that Valos might interact with certain blood pressure medicines?

Regulatory documents note potential interactions with medicines like diuretics and other substances classified as nephrotoxic agents. Because some blood pressure treatments may fall into these categories, it is important to confirm the full list of medications against the official interaction profile.

Q: Are Valos side effects permanent?

Most adverse reactions described in the official safety profile are temporary and generally resolve after the drug is stopped. However, rare and severe effects affecting organs like the kidneys or liver have been reported, and these specific reactions could potentially lead to longer-term health consequences.

Q: Is Valos a habit-forming medicine?

Valos is classified as a non-scheduled antibiotic, and official information does not designate it as a habit-forming or addictive substance.

Q: Why do some people report feeling tired on Valos?

Fatigue, or unusual tiredness, is listed among the possible adverse reactions in some regulatory summaries for this medicine. It is a documented effect within the drug's safety profile.

Q: Are there any documented interactions between Valos and alcohol?

The primary interaction summaries do not always list alcohol specifically. However, official regulatory warnings for antibiotics often include the precaution of avoiding alcohol consumption during the treatment period.

Q: Is Valos officially approved in other countries besides the US?

The generic active ingredient, Cefadroxil, is approved for use by numerous regulatory bodies worldwide. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Can Valos be used by people with diabetes?

Official warnings state that Valos can interfere with specific non-enzyme-based tests used to check for glucose (sugar) in the urine, potentially causing a false-positive result. If urine glucose testing is necessary during treatment, the official product labeling states that an enzymatic method should be used due to potential interference.

Q: Are there different strengths of Valos available?

The medicine is supplied in various formulations, including tablets, capsules, and a powder for oral suspension. The official product labeling confirms that these forms are available in multiple marketed strengths (e.g., 500 mg and 1000 mg).

Q: What is the estimated duration of Valos's effects in the body?

Pharmacokinetic data from official sources indicate the medicine is rapidly absorbed after administration. The elimination half-life—the time it takes for half the drug to be removed from the body—is approximately 1 to 2 hours in individuals whose kidney function is normal.

Q: Why do I need a prescription for Valos?

Valos is designated as a Prescription Only (Rx) medicine by regulatory bodies. This classification is required because it is an antibiotic, and its administration requires professional supervision to ensure correct use, which is critical for preventing the development of antibiotic resistance.

Q: How is the need for continued Valos treatment generally evaluated?

Official guidelines advise that for prolonged courses of treatment, healthcare providers should evaluate the patient's condition through regular monitoring. This may include periodic checks of blood counts and assessments of both liver (hepatic) and kidney (renal) function.

Q: How is Valos packaged?

Valos is supplied in packaging designed to protect the medicine, which includes bottles or blister packs for tablets and capsules, and sealed containers for the oral powder. The exact type of packaging and the quantity of medicine it contains depends on the specific form and strength being dispensed.

How should Valos be stored and disposed of?

How to Store and Dispose of Valos

The storage requirements for Valos (Cefadroxil) depend on the formulation and must adhere strictly to regulatory conditions to maintain stability.

Storage Requirements

Product Form Temperature Requirement Stability Constraint
Capsules/Tablets Store at Controlled Room Temperature (15 C to 30 C) Protect from excess heat and moisture.
Oral Suspension Store in a refrigerator Must be discarded 14 days after reconstitution. Do not freeze.

The medication must always be kept in its original container, tightly closed, and stored out of the sight and reach of children.

Disposal

Discard any unused or expired Valos according to local regulations. The preferred method is through a drug take-back program. If unavailable, mix the medicine with an undesirable substance (e.g., used coffee grounds) and place it in a sealed bag for disposal in household trash. Do not flush Valos down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valos found in:

A-Z Index: